Production and Preliminary in vivo Evaluations of a Novel in silico-Designed L2-based Potential HPV Vaccine.
L2-based human papillomavirus (HPV) prophylactic vaccines, containing epitopes from HPV minor capsid proteins, are under investigation as second generation HPV vaccines. No such vaccine has passed clinical trials yet, mainly due to the low immunogenicity of peptide vaccines; so efforts are being continued. A candidate vaccine composed of two HPV16 L2 epitopes, flagellin and a toll-like receptor (TLR) 4 agonist (RS09) as adjuvants, and two universal T-helper epitopes was designed in silico in our previous researches. The designed vaccine construct was expressed in E. coli BL21 (DE3) and purified through metal affinity chromatography. Following mice vaccination, blood samples underwent ELISA and flow cytometry analyses for detection of IgG and seven Th1 and Th2 cytokines. Following immunization, Th1 (IFN-γ, IL-2) and Th2 (IL-4, IL-5, IL-10) type cytokines as well as IgG were induced significantly compared to the PBS group. Significant increases in IFN-γ, IL-2, and IL-5 levels were observed in the vaccinated group versus Freund's adjuvant group. The obtained cytokine induction profile implied both cellular and humoral responses, with a more Th-1 favored trend. No significant elevation in inflammatory cytokines, (IL-6 and TNF-α), suggests lack of unwanted inflammatory side effects despite using a combination of two TLR agonists. The designed vaccine might be capable of inducing adaptive and innate immunity and deserves more specific future investigations.